Ashish Saxena (2018) Molecular Testing for Stage IV Non–Small Cell Lung Cancer Patients with Targetable Mutations Following Disease Progression. Archives of Pathology & Laboratory Medicine In-Press.

Early Online Release

Molecular Testing for Stage IV Non–Small Cell Lung Cancer Patients with Targetable Mutations Following Disease Progression

Ashish Saxena, MD, PhD

From the Department of Medicine, Division of Hematology & Medical Oncology, Thoracic Oncology Service, Weill Cornell Medicine, New York, New York. Dr Saxena has received honoraria and consulting fees from Genentech, Lily Oncology, Clovis Oncology, AstraZeneca, Takeda, ARIAD Pharmaceuticals, GfK, and Guardant Health.

"...the updated guidelines from the Association for Molecular Pathology (AMP), the International Association for the Study of Lung Cancer (IASLC), and the College of American Pathologists (CAP) have sought to give guidance on the testing that is indicated for patients with actionable mutations who have relapsed on targeted therapy."